Not Yet RecruitingNCT06924255
Switching to xanomeline and trospium for schizophrenia
About this title
Read the official source — NCT06924255Medication studyAges 18–65United States
Understand this study
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Bellflower and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: April 2025
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 100
- Sponsor
- Collaborative Neuroscience Research, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06924255
- Official title
Show the full official title
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants With DSM-5 Schizophrenia
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bellflower · Garden Grove · Riverside
4 more locations
- Torrance
- Hollywood
- Gaithersburg
- Marlton
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Collaborative Neuroscience Research, LLC.
Does this study involve medication?
Yes. The study involves medication, including Xanomeline and Trospium Chloride.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
